Recorded Webinar from October 30, 2019
Complement protein C5a is recognized as an important component of the alternative complement pathway. Bioanalytical challenges have been posed in proper quantitation of free C5a due to interference from its precursor, C5. Additionally, free therapeutic target quantitation can be difficult due to effects of sample dilution and prolonged sample incubation when therapeutic is used as capture reagent. Gyrolab technology enables quantitation of free target analyte with minimal sample dilution and rapid sample incubation, thus enabling in vitro results that are more representative of in vivo pharmacodynamics. When coupled with strategic sample pretreatment, Gyrolab offers an opportunity to quantitate free C5a in human plasma with an assay that vastly diminishes C5 interference. A Gyrolab assay for the quantitation of free C5a in human plasma was developed and validated. Validation results confirmed that proper sample pre-treatment and use of the Gyrolab platform yield accurate and reliable results. Due to the advantages that it provides, Gyrolab has become our default technology of choice for quantitation of free target.
This educational webinar will be helpful for those involved with:
• Ligand binding assays interested in maximizing performance and productivity
• Free target biomarker studies and solving for overestimation of target
Mark Dysinger, M.S.
Development Scientist III
If you have problems to view the webinar please contact firstname.lastname@example.org